Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMML

NCT03922100 is registered in ClinicalTrials.gov with Nerviano Medical Sciences as lead sponsor.

NCT NCT03922100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03922100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMML
Lead sponsor
Nerviano Medical Sciences
Phase
Phase 1/2
Overall status
Terminated
Start date
April 3, 2019
Completion date
August 29, 2024
Enrollment
63 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), chronic myelomonocytic leukemia (cmml)